Weizmann-led study links histone modification patterns to breast cancer diagnosis
Researchers analyzed histone post-translational modifications in breast tumor tissue, blood plasma, and patient-derived xenograft models to characterize epigenetic variation within breast tumors. The work combined samples from institutions including the European Institute of Oncology, Mayo Clinic, Sheba Medical Center, and the Weizmann Institute of Science, using mass-spectrometry-based analysis and mouse models implanted with human tumor tissue.
GoKawiil's interpretation of the reporting above, not reported fact.
Mapping how histone modifications vary across tumor cells could offer new biomarkers for distinguishing cancer subtypes or predicting disease progression, beyond standard genetic mutation analysis. If validated further, such epigenetic profiling might eventually support less invasive diagnostic or prognostic tools using blood plasma rather than tissue biopsies.
- Study examined histone modification diversity in breast tumors using tissue, plasma, and xenograft samples.
- Multiple international institutions contributed patient samples under separate ethics approvals.
- Findings could inform future epigenetic approaches to breast cancer diagnosis and prognosis.
Source: nature.com — Furth, 2026-11-11
Published there as: “Epigenetic heterogeneity in breast tumours informs diagnosis and prognosis”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.